SCHEMBL347124

SCHEMBL347124

Cc1nc(NC(C)CN)sc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.47
ALDH1A1 P00352 5/20 0.44
HPGD P15428 3/20 0.44
TSHR P16473 1/20 0.44
GAA P10253 3/20 0.43
RXFP1 Q9HBX9 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
HTT P42858 1/20 0.43
PKM P14618 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
PFKFB3 Q16875 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
TARBP2 Q15633 1/20 0.39
CCNA2 P20248 1/20 0.38
CDK2 P24941 1/20 0.38
PDE5A O76074 1/20 0.38
PDE1A P54750 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1911617 0.83 ALDH1A1 (0.60) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL1911619 0.83 ALDH1A1 (0.60) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL23815714 0.77 RXFP1 (0.59) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL347225 0.76 NPC1 (0.53) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL22750815 0.75 ALDH1A1 (0.53) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL8554963 0.73 ALDH1A1 (0.55) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL25410224 0.73 RXFP1 (0.77) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL14729401 0.72 NPC1 (0.44) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL18145629 0.72 NPC1 (0.44) NPC1ALDH1A1HPGDTSHRGAA
SCHEMBL8556409 0.72 NPC1 (0.60) NPC1ALDH1A1HPGDTSHRGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318949-B2 Organic compounds NOVARTIS AG (CH) 2012-11-27 US disclosed
US-20120014906-A1 ORGANIC COMPOUNDS XENON PHARMACEUTICALS INC. (CA) 2012-01-19 US disclosed
US-8049016-B2 Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes NOVARTIS AG (CH) 2011-11-01 US disclosed
US-20090264444-A1 Organic compounds XENON PHARMACEUTICALS INC. (CA) 2009-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120014906-A1 ORGANIC COMPOUNDS SCD, SCD5, FADS2 NPC1 228/4885ALDH1A1 451/4885HPGD 344/4885
US-20090264444-A1 Organic compounds SCD, SCD5, FADS2 NPC1 228/4885ALDH1A1 451/4885HPGD 344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.